2023 RET Cancer Research Update
2023 Happy Lungs Project RET research update On Friday December 8th, the Happy Lungs Project…
Irene Guijarro MunozDecember 18, 2023
Exciting Preclinical Results About Vepafestinib
New published study with exciting preclinical results about the second generation RET inhibitor vepafestinib (TAS0953/HM06). Vepafestinib showed selectivity…
Irene Guijarro MunozOctober 10, 2023
Two research studies funded by HLP presented at 2023 ASCO Mtg
Last week was the 2023 American Society of Clinical Oncology (ASCO) conference in Chicago. The…
Irene Guijarro MunozJune 19, 2023
Ellipses Pharma presents ‘encouraging’ data on selective RET inhibitors
Data of the Phase 1 Study of KL590586 (EP0031/A400), presented at ASCO, reported preliminary efficacy…
Irene Guijarro MunozJune 19, 2023
DAVA’s 2nd Hawaii Global Summit on Thoracic Malignancies
The DAVA’s 2nd Hawaii Global Summit on Thoracic Malignancies is a five-day meeting comprising seven…
Irene Guijarro MunozJune 19, 2023
Virtual Event: 2022 RET Cancer Research Update (Watch Video)
The Happy Lungs Project hosted a 2022 Research Update, featuring presentations about advances for RET-positive…
Irene Guijarro MunozDecember 13, 2022
Participants Needed: Epidemiology of Young Lung Cancer Study
Epidemiology of Young Lung Cancer is a clinical study for patients who were diagnosed with…
Irene Guijarro MunozNovember 29, 2022
Press Release: Happy Lungs Shopping Card Raised Thousands for Lung Cancer Research
HAPPY LUNGS SHOPPING CARD SUCCESSFUL IN AUSTIN PREMIER, RAISING THOUSANDS FOR LUNG CANCER RESEARCH, GENERATING RETAIL…
Irene Guijarro MunozNovember 15, 2022
Dr. Irene Guijarro Munoz Named Our Science Liaison & Research Manager
Dr. Irene Guijarro Munoz has been named the Science Liaison and Research Manager for the…
Irene Guijarro MunozSeptember 27, 2022
Press Release: Partnering on Innovative Lung Cancer Research
The Happy Lungs Project is pleased to share research that we are funding in collaboration…
Irene Guijarro MunozMay 31, 2022
